Shilpa Medicare unit acquires 30.4% stake in Gate2Brain for €7 million
Shilpa Medicare's wholly owned subsidiary, Shilpa Biocare Pvt Ltd, has acquired a 30.4% stake in Gate2Brain, S.L. for €7 million to advance G2B-002, a first-in-class brain cancer therapy. The partnership designates Shilpa Biocare as the CMC, manufacturing, and regulatory partner, targeting first-in-human trials by FY28.
*this image is generated using AI for illustrative purposes only.
Shilpa Medicare has announced that its wholly owned subsidiary, Shilpa Biocare Pvt Ltd, has entered into a strategic equity partnership with Gate2Brain, S.L., acquiring a 30.4% stake for a total consideration of €7 million. This collaboration focuses on advancing G2B-002, a first-in-class brain cancer therapy that has been granted Orphan Drug Designation by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The partnership designates Shilpa Biocare as the dedicated CMC, manufacturing, and regulatory partner for the program, aiming to bring the treatment to first-in-human trials by FY28.
Transaction Details
The acquisition involves a mix of cash infusion and equity for services, structured to support the development of Gate2Brain's proprietary peptide-shuttle platform. The transaction does not constitute a related party transaction and will be completed in various tranches as per definitive agreements.
| Parameter | Details |
|---|---|
| Acquiring Entity | Shilpa Biocare Pvt Ltd (Wholly Owned Subsidiary) |
| Target Entity | Gate2Brain, S.L. |
| Stake Acquired | 30.4% |
| Total Consideration | €7 million |
| Cash Infusion | €0.5 million |
| Equity for Services | €5.5 million |
| Development Funding | €1 million |
Strategic Focus and Regulatory Status
Gate2Brain is a Barcelona-based biotechnology company incorporated under Spanish laws, specializing in peptide-based delivery systems that transport therapeutics across the blood-brain barrier. Its lead candidate, G2B-002, utilizes the proprietary MiniAp4 peptide shuttle to deliver SN-38, a potent anticancer agent, directly to brain tumors. The drug targets diffuse intrinsic pontine glioma (DIPG) and pediatric glioblastoma (pGBM), addressing critical unmet medical needs in rare and aggressive pediatric and adult brain cancers.
The Orphan Drug Designation from the US FDA and EMA validates the potential of G2B-002 to treat these rare conditions. Preclinical studies indicate the MiniAp4 platform can achieve up to 100-fold greater brain drug transport compared to conventional approaches, with potential applications extending to other rare pediatric cancers such as Ewing sarcoma and neuroblastoma.
Management Commentary
Vishnukant Bhutada, Managing Director of Shilpa Medicare Ltd, highlighted the strategic value of the investment, stating that becoming a shareholder allows the company to participate in long-term value creation while contributing essential manufacturing and regulatory depth. Meritxell Teixidó Turà, CEO of Gate2Brain, noted that the partnership provides a de-risked path to the clinic and validates the platform with a top-tier oncology partner. This transaction marks Shilpa Medicare's fourth strategic equity partnership, reinforcing its strategy of investing in differentiated innovation within the oncology and rare disease segments.
Historical Stock Returns for Shilpa Medicare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.02% | +6.91% | +29.30% | +56.98% | +20.20% | +90.92% |
What are the key milestones and timelines expected for the G2B-002 first-in-human trials leading up to FY28?
How will Shilpa Medicare leverage the MiniAp4 platform for potential applications in other rare pediatric cancers like Ewing sarcoma and neuroblastoma?
What are the potential market exclusivity benefits and commercial opportunities resulting from the Orphan Drug Designation granted by the FDA and EMA?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
